Journal of Isfahan Medical School

Journal of Isfahan Medical School

The Effect of Bromocriptine on the Disease Activity Index in Patients with Rheumatoid Arthritis

Document Type : Original Article (s)

Authors
Mansour Salesi 1
Somayeh Sadeghi Haddadzavareh 2
Peyman Nasri 3
Nasrin Namdari Gharaghani 2
Ziba Farajzadegan 4
1 Assistant Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Pediatrician, Department of Pediatrics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
4 Associate Professor, Department of Community and Preventive Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
Background: Limited studies have shown that the administration of Bromocriptine leads to clinical improvement in a number of rheumatic patients. Low price of Bromocriptine and its trivial side effects lead the authors to investigating the effect of Bromocriptine on rheumatoid arthritis (RA) disease activity.Methods: In a randomized controlled double-blinded quasi-experimental study the effectiveness of Bromocriptine in treating rheumatoid arthritis was evaluated. 80 patients were divided in two groups (experiment and placebo. The inclusion criteria were the presence of active rheumatoid arthritis (DAS > 3.2) in spite of medical treatment. In addition to the standard medications, the case group received single oral doses of 5 mg bromocriptine and the control group received placebo tablet and  were followed up for three months. Independent T-test was used to compare DAS28 in the two groups. P < 0.05 was considered significant.Finding: The mean ages of the experiment and placebo groups were 46.2 ± 13.0 and 45.9 ± 12.5 respectively. Before the starting pf the intervention in the experiment group, the mean values of PRL and DAS were 11.7 ± 6.9 and 4.2 ± 1.2, and the mean values of PRL and DAS in the placebo group were 11.3 ± 6.2 and 4.6 ± 1.4 respectively (P > 0.05). After the intervention the mean values of serum PRL level and DAS in the experiment group were 10.6 ± 7.1 and 3.7 ± 1.3 respectively, that were different with those of before the intervention (P < 0.05).Conclusion: Our findings suggest that Bromocriptine might be effective in decreasing the rheumatoid arthritis disease activity index, without any concerns about side effects.
Keywords
Bromocriptine
Rheumatoid arthritis
Prolactin
Disease activity index
  1. Jara LJ, Lavalle C, Fraga A, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, et al. Prolactin, immunoregulation, and autoimmune diseases. Semin Arthritis Rheum 1991; 20(5): 273-84.
  2. Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26(3): 118-23.
  3. Walker SE. Prolactin: an immune-stimulating peptide that regulates other immune-modulating hormones. Lupus 1993; 2(2): 67-9.
  4. Reber PM. Prolactin and immunomodulation. Am J Med 1993; 95(6): 637-44.
  5. Gutierez MA, Anaya JM, Cabrera GE, Vindrola O, Espinoza LR. [Prolactin, a link between the neuroendocrine and immune systems. Role in the pathogenesis of rheumatic diseases]. Rev Rhum Ed Fr 1994; 61(4): 278-85.
  6. Buskila D, Shoenfeld Y. Prolactin, bromocriptine and autoimmune diseases. Isr J Med Sci 1996; 32(1): 23-7.
  7. Compan Gonzalez DA, Martinez Aguilar NE, Vargas Camano ME, Guido BR. [Hyperprolac-tinemia and autoimmunity]. Rev Alerg Mex 1996; 43(5): 128-32.
  8. Leanos MA, Quintal Alvarez MG, Cervera CH, Blanco FF. [Prolactin as an immunomodulator]. Rev Alerg Mex 1997; 44(5): 116-23.
  9. McMurray RW. Estrogen, prolactin, and auto-immunity: actions and interactions. Int Im-munopharmacol 2001; 1(6): 995-1008.
  10. Frantz AG. Prolactin. N Engl J Med 1978; 298(4): 201-7.
  11. Franks S. Regulation of prolactin secretion by oestrogens: physiological and pathological sig-nificance. Clin Sci (Lond) 1983; 65(5): 457-62.
  12. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 1997; 4(4): 171-80.
  13. Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, et al. Prolactin synthesized and se-creted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphopro-liferation. Proc Natl Acad Sci USA 1992; 89(16): 7713-6.
  14. Kelly PA, Djiane J, Edery M. Different forms of the prolactin receptor: insights into the mecha-nism of prolactin action. Trends Endocrinol Metab 1992; 3(2): 54-9.
  15. Yu-Lee LY, Stevens AM. Hrachovy JA, Schwarz LA. Prolactin-mediated regulation of gene tran-scription in lymphocytes. Ann N Y Acad Sci 1990; 594: 146-55.
  16. McMurray RW. Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum 2001; 31(1): 21-32.
  17. Ascoli M, Segaloff DL. Adenohypophyseal hor-mones and their hypothalamic releasing factors. In: Goodman and Gilman’s The Pharmacologi-cal Basis of Therapeutics (9th ed), Harmon JG, Limband LF, eds. New York, McGraw-Hill 1996; 1371-2.
  18. Parkes D. Bromocriptine. Adv Drug Res 1977; 12: 247-344.
  19. Morikawa K, Oseko F, Morikawa S. Immuno-suppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immu-nol 1994; 95(3): 514-8.
  20. Morkawa K, Oseko F, Morikawa S. Immuno-suppressive property of bromocriptine on human B lymphocyte function in vitro. Clin Exp Immu-nol 1993; 93(2): 200-5.
  21. Schaaf L, Zierhut M, Baur EM, Geissler W, Thiel HJ, Seif FJ, et al. Bromocriptine in patients with chronic autoimmune-associated disorders. Klin Wochenschr 1991; 69(20): 943.
  22. Lopez-Karpovitch X, Larrea F, Cardenas R, Va-lencia X, Piedras J, Diaz-Sanchez V, et al. Cellu-lar and humoral immune parameters in women with pathological hyperprolactinemia before and during treatment with bromocriptine. Am J Re-prod Immunol 1994; 31(1): 32-9.
  23. McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythemato-sus. J Rheumatol 1995; 22(11): 2084-91.
  24. Blank M, Palestine A. Nussenblatt R, Shoenfeld Y. Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in pa-tients with uveitis. Clin Immunol Immunopathol 1990; 54(1): 87-97.
  25. Smith PE. The effect of hypophysectomy upon the involution of the thymus in the rat. Anat Rec 1930; 47(1): 119-29.
  26. Stevens A, Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene--implications for production of lymphocyte pro-lactin and systemic lupus erythematosus. Lupus 2001; 10(10): 676-83.
  27. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Es-calante-Triay F, Sosa-Munoz J, Miranda JM, Ja-ra LJ. Bromocriptine in systemic lupus erythe-matosus: a double-blind, randomized, placebo-controlled study. Lupus 1998; 7(6): 414-9.
  28. Figueroa F, Carrion F, Martinez ME, Rivero S, Mamani I, Gonzalez G. [Effects of bromocripti-ne in patients with active rheumatoid arthritis]. Rev Med Chil 1998; 126(1): 33-41.
  29. Figueroa FE, Carrion F, Martinez ME, Rivero S, Mamani I. Bromocriptine induces immunologi-cal changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 1997; 36(9): 1022-3.
  30. Mader R. [Bromocriptine for refractory rheuma-toid arthritis]. Harefuah 1997; 133(11): 527-9, 591.
  31. Leiderman S, Gurfinkiel M, Damilano S, Lago RA, Martins S, Rosman F, et al. Prolactin and IgG-prolactin complex levels in patients with rheumatic arthritis. Ann N Y Acad Sci 2002; 966: 252-7.
  32. Seriolo B, Ferretti V, Sulli A, Fasciolo D, Cutolo M. Serum prolactin concentrations in male pa-tients with rheumatoid arthritis. Ann N Y Acad Sci 2002; 966: 258-62.
  33. Templ E, Koeller M, Riedl M, Wagner O, Gran-inger W, Luger A. Anterior pituitary function in patients with newly diagnosed rheumatoid arthri-tis. Br J Rheumatol 1996 Apr;35(4):350-6.
  34. Jorgensen C, Bressot N, Bologna C, Sany J. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol 1995; 22(10): 1829-33.
  35. Halko G, Urrows S, Affleck G, Waterman J. Se-rum prolactin levels and disease activity in rheumatoid arthritis. Arthritis Rheum 1995; 38: S289.
  36. Ram S, Blumberg D, Newton P, Anderson NR, Gama R. Raised serum prolactin in rheumatoid arthritis: genuine or laboratory artefact? Rheu-matology (Oxford) 2004; 43(10): 1272-4.
  37. Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sa-kane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheuma-toid arthritis. J Rheumatol 1999; 26(9): 1890-900.
  38. Dougados M, Duchesne L, Amor B. Bromocrip-tine and cyclosporin a combination therapy in rheumatoid arthritis. Arthritis Rheum 1988; 31(10): 1333-4.
  39. Marguerie C, David J, So A, Walport M. A pilot study comparing bromocriptine with D-penicillamine in the treatment of rheumatoid ar-thritis. Br J Rheumatol 1990; 29 suppl 2: 3.
Journal of Isfahan Medical School
Volume 29, Issue 133 - Serial Number 133
March and April 2011
Pages 344-352

  • Receive Date 05 March 2011
  • Accept Date 06 April 2022